PMID: 9174183Jun 1, 1997Paper

Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients

Antimicrobial Agents and Chemotherapy
V HeinemannW Wilmanns

Abstract

The liposomal formulation of amphotericin B (AmBisome) greatly reduces the acute and chronic side effects of the parent drug. The present study describes the pharmacokinetic characteristics of AmBisome applied to 10 patients at a dose of 2.8 to 3.0 mg/kg of body weight and compares them to the pharmacokinetics observed in 6 patients treated with amphotericin B deoxycholate at the standard dose of 1.0 mg/kg. Interpatient variabilities of amphotericin B peak concentrations (Cmax) and areas under concentration-time curves (AUC) were 8- to 10-fold greater for patients treated with AmBisome than for patients treated with amphotericin B deoxycholate. At the threefold greater dose of AmBisome, median Cmaxs were 8.4-fold higher (14.4 versus 1.7 microg/ml) and median AUCs exceeded those observed with amphotericin B deoxycholate by 9-fold. This was in part explained by a 5.7-fold lower volume of distribution (0.42 liters/kg) in AmBisome-treated patients. The elimination of amphotericin B from serum was biphasic for both formulations. However, the apparent half-life of elimination was twofold shorter for AmBisome (P = 0.03). Neither hemodialysis nor hemofiltration had a significant impact on AmBisome pharmacokinetics as analyzed in one pa...Continue Reading

References

Oct 1, 1992·Clinical Pharmacokinetics·R JanknegtD J Crommelin
Aug 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·E AnaissieG P Bodey
Oct 1, 1991·The Journal of Antimicrobial Chemotherapy·G Gregoriadis
Oct 1, 1991·The Journal of Antimicrobial Chemotherapy·R T ProffittJ P Adler-Moore
Oct 1, 1991·The Journal of Antimicrobial Chemotherapy·J P Adler-MooreR T Proffitt
Oct 1, 1991·The Journal of Antimicrobial Chemotherapy·F MeunierO Ringdén
Oct 1, 1991·The Journal of Antimicrobial Chemotherapy·R ChopraA H Goldstone
Dec 1, 1991·Blood Reviews·A Gray, J Morgan
Mar 1, 1990·Reviews of Infectious Diseases·H A GallisW W Pickard
May 1, 1987·Antimicrobial Agents and Chemotherapy·G Lopez-Berestein
Mar 1, 1988·European Journal of Cancer & Clinical Oncology·J P SculierJ Klastersky
Dec 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A BurchE K Fishman
Nov 1, 1985·The Journal of Infectious Diseases·K J ChristiansenD Armstrong
Sep 1, 1973·Antimicrobial Agents and Chemotherapy·H A FeldmanR A Gutman
Oct 1, 1969·The Journal of Infectious Diseases·D D Bindschadler, J E Bennett
Jun 1, 1970·Applied Microbiology·B T FieldsR S Abernathy
Mar 14, 1984·Biochimica Et Biophysica Acta·R MehtaR L Juliano
May 1, 1994·The Journal of Antimicrobial Chemotherapy·H HumphreysD W Warnock
Feb 1, 1994·The Journal of Antimicrobial Chemotherapy·S H KhooD W Denning

❮ Previous
Next ❯

Citations

Jun 29, 2001·Transplant Infectious Disease : an Official Journal of the Transplantation Society·M Ellis
Jun 29, 2001·Transplant Infectious Disease : an Official Journal of the Transplantation Society·M TiphineR Herbrecht
Jul 29, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Luis Ostrosky-ZeichnerStuart H Cohen
Jul 25, 2009·The Journal of Membrane Biology·Eneida A RomeroB Eleazar Cohen
Aug 2, 2012·Antimicrobial Agents and Chemotherapy·Stefan WeilerRomuald Bellmann
Apr 16, 2014·Biomedical Chromatography : BMC·Bushra T Al-QuadeibAbdulaziz Alshaer
Aug 2, 2017·Clinical Pharmacokinetics·Anke E KipThomas P C Dorlo
Apr 18, 2019·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Kaitlin BranickGeoffrey C Wall
May 28, 2005·Expert Review of Anti-infective Therapy·Winter J GibbsJohn R Perfect
Jul 1, 2006·Journal of Clinical Pharmacology·Agop Y BedikianRostam Namdari
Jan 8, 2020·Pharmaceutics·Célia Faustino, Lídia Pinheiro
Apr 20, 2002·Current Opinion in Infectious Diseases·Rosemary A. Barnes
May 27, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Romuald BellmannChristian J Wiedermann
Feb 13, 2020·Revista Da Sociedade Brasileira De Medicina Tropical·Leticia Aparecida SchiaveRoberto Martinez
Jun 30, 2019·Mycoses·Oliver A CornelyUNKNOWN Mycoses Study Group Education and Research Consortium (MSG-ERC) and the European Confederation of Medical Mycology (ECMM)
Sep 26, 2019·Expert Opinion on Drug Metabolism & Toxicology·Jamie JohnThomas J Walsh
Jun 22, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andreas H GrollRoger J M Brüggemann
Feb 2, 2021·Infectious Diseases and Therapy·Francelise B CavassinFlávio Queiroz-Telles
Nov 24, 2018·Médecine et maladies infectieuses·J B FoulquierF Lemaitre
Jan 2, 2013·Chemical Reviews·Venkat Ratnam DevadasuM N V Ravi Kumar
Jun 20, 2015·Chemical Reviews·Yuanzeng MinAndrew Z Wang
Sep 30, 2020·Current Drug Metabolism·Xuan YuChen Cheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.